Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study

• Published in: Diabetes therapy 2024-06, Vol.15 (6), p.1313-1331
• Main Authors: Di Loreto, Chiara, Celleno, Roberta, Pezzuto, Debora, Ambrosi, Franca, Bellavita, Silvia, Biagini, Marinella, Passeri, Monica, Del Sindaco, Paola
• Format: Article
• Language: English
• Subjects: Antidiabetics; Body mass index; Cardiology; Chronic illnesses; Clinical medicine; Diabetes; Diagnosis; Dosage and administration; Drug therapy; Endocrinology; Glucagon; Glucose; Glycosylated hemoglobin; Health aspects; Hypoglycemia; Hypoglycemic agents; Insulin; Internal Medicine; Measurement; Medicine; Medicine & Public Health; Metabolism; Observational studies; Original Research; Patient outcomes; Patients; Type 2 diabetes
• ISSN: 1869-6953; 1869-6961
• DOI: 10.1007/s13300-024-01564-z

Introduction Efficacy and safety of the fixed ratio combination of insulin degludec and liraglutide (IDegLira) has been largely documented. However, long-term data are limited. This study aimed at describing persistence in therapy and the effectiveness at 48 months of IDegLira. Methods We conducted an observational study based on retrospective chart review. All patients treated with IDegLira during 2018–2022 were included. Data on treatment approaches and clinical outcomes were collected at the first prescription of IDegLira (T0) and after 6, 12, 24, 36, and 48 months. Results Overall, 156 patients (mean age 68 years, 64.1% men) started IDegLira, of whom 88 (56.4%) were previously treated with basal-oral therapy (BOT) and 68 (43.6%) with basal-bolus schemes (BB). Before starting IDegLira, 23.8% were treated with ≥ 2 oral antihyperglycemic agents in association with insulin; at T0, the proportion decreased to 3.2%. Short-acting insulin was discontinued after the first week. After 48 months, levels of HbA1c were significantly reduced by 1.34% in the BOT group and 1.07% in the BB group ( p